Magnitude of cognitive dysfunction in adults with type 2 diabetes: A meta-analysis of six cognitive domains and the most frequently reported neuropsychological tests within domains

Priya Palta, Andrea L C Schneider, Geert Jan Biessels, Pegah Touradji, Felicia Hill-Briggs

Research output: Contribution to journalArticle

Abstract

The objectives were to conduct a meta-analysis in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standards to determine effect sizes (Cohen's d) for cognitive dysfunction in adults with type 2 diabetes, relative to nondiabetic controls, and to obtain effect sizes for the most commonly reported neuropsychological tests within domains. Twenty-four studies, totaling 26,137 patients (n = 3351 with diabetes), met study inclusion criteria. Small to moderate effect sizes were obtained for five of six domains: motor function (3 studies, n = 2374; d = -0.36), executive function (12 studies, n = 1784; d = -0.33), processing speed (16 studies, n = 3076; d = -0.33), verbal memory (15 studies, n = 4,608; d = -0.28), and visual memory (6 studies, n = 1754; d = -0.26). Effect size was smallest for attention/concentration (14 studies, n = 23,143; d = -0.19). The following tests demonstrated the most notable performance decrements in diabetes samples: Grooved Pegboard (dominant hand) (d = -0.60), Rey Auditory Verbal Learning Test (immediate) (d = -0.40), Trails B (d = -0.39), Rey-Osterreith Complex Figure (delayed) (d = -0.38), Trails A (d = -0.34), and Stroop Part I (d = -0.28). This study provides effect sizes to power future epidemiological and clinical diabetes research studies examining cognitive function and to help inform the selection of neuropsychological tests.

Original languageEnglish (US)
Pages (from-to)278-291
Number of pages14
JournalJournal of the International Neuropsychological Society
Volume20
Issue number3
DOIs
StatePublished - Feb 24 2014

Fingerprint

Neuropsychological Tests
Type 2 Diabetes Mellitus
chronic illness
Meta-Analysis
Verbal Learning
Executive Function
Cognition
Hand
motor function
Research
inclusion
Cognitive Dysfunction
Type 2 Diabetes
Meta-analysis
Effect Size
learning
performance
Diabetes
Power (Psychology)
Trails

Keywords

  • Assessment
  • Cardiovascular disease
  • Central nervous system
  • Chronic disease
  • Endocrine
  • Metabolic disorders

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Clinical Psychology
  • Neuroscience(all)
  • Language and Linguistics
  • Linguistics and Language

Cite this

@article{6e2b7ebab9a544b8be39d07264c200bb,
title = "Magnitude of cognitive dysfunction in adults with type 2 diabetes: A meta-analysis of six cognitive domains and the most frequently reported neuropsychological tests within domains",
abstract = "The objectives were to conduct a meta-analysis in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standards to determine effect sizes (Cohen's d) for cognitive dysfunction in adults with type 2 diabetes, relative to nondiabetic controls, and to obtain effect sizes for the most commonly reported neuropsychological tests within domains. Twenty-four studies, totaling 26,137 patients (n = 3351 with diabetes), met study inclusion criteria. Small to moderate effect sizes were obtained for five of six domains: motor function (3 studies, n = 2374; d = -0.36), executive function (12 studies, n = 1784; d = -0.33), processing speed (16 studies, n = 3076; d = -0.33), verbal memory (15 studies, n = 4,608; d = -0.28), and visual memory (6 studies, n = 1754; d = -0.26). Effect size was smallest for attention/concentration (14 studies, n = 23,143; d = -0.19). The following tests demonstrated the most notable performance decrements in diabetes samples: Grooved Pegboard (dominant hand) (d = -0.60), Rey Auditory Verbal Learning Test (immediate) (d = -0.40), Trails B (d = -0.39), Rey-Osterreith Complex Figure (delayed) (d = -0.38), Trails A (d = -0.34), and Stroop Part I (d = -0.28). This study provides effect sizes to power future epidemiological and clinical diabetes research studies examining cognitive function and to help inform the selection of neuropsychological tests.",
keywords = "Assessment, Cardiovascular disease, Central nervous system, Chronic disease, Endocrine, Metabolic disorders",
author = "Priya Palta and Schneider, {Andrea L C} and Biessels, {Geert Jan} and Pegah Touradji and Felicia Hill-Briggs",
year = "2014",
month = "2",
day = "24",
doi = "10.1017/S1355617713001483",
language = "English (US)",
volume = "20",
pages = "278--291",
journal = "Journal of the International Neuropsychological Society",
issn = "1355-6177",
publisher = "Cambridge University Press",
number = "3",

}

TY - JOUR

T1 - Magnitude of cognitive dysfunction in adults with type 2 diabetes

T2 - A meta-analysis of six cognitive domains and the most frequently reported neuropsychological tests within domains

AU - Palta, Priya

AU - Schneider, Andrea L C

AU - Biessels, Geert Jan

AU - Touradji, Pegah

AU - Hill-Briggs, Felicia

PY - 2014/2/24

Y1 - 2014/2/24

N2 - The objectives were to conduct a meta-analysis in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standards to determine effect sizes (Cohen's d) for cognitive dysfunction in adults with type 2 diabetes, relative to nondiabetic controls, and to obtain effect sizes for the most commonly reported neuropsychological tests within domains. Twenty-four studies, totaling 26,137 patients (n = 3351 with diabetes), met study inclusion criteria. Small to moderate effect sizes were obtained for five of six domains: motor function (3 studies, n = 2374; d = -0.36), executive function (12 studies, n = 1784; d = -0.33), processing speed (16 studies, n = 3076; d = -0.33), verbal memory (15 studies, n = 4,608; d = -0.28), and visual memory (6 studies, n = 1754; d = -0.26). Effect size was smallest for attention/concentration (14 studies, n = 23,143; d = -0.19). The following tests demonstrated the most notable performance decrements in diabetes samples: Grooved Pegboard (dominant hand) (d = -0.60), Rey Auditory Verbal Learning Test (immediate) (d = -0.40), Trails B (d = -0.39), Rey-Osterreith Complex Figure (delayed) (d = -0.38), Trails A (d = -0.34), and Stroop Part I (d = -0.28). This study provides effect sizes to power future epidemiological and clinical diabetes research studies examining cognitive function and to help inform the selection of neuropsychological tests.

AB - The objectives were to conduct a meta-analysis in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standards to determine effect sizes (Cohen's d) for cognitive dysfunction in adults with type 2 diabetes, relative to nondiabetic controls, and to obtain effect sizes for the most commonly reported neuropsychological tests within domains. Twenty-four studies, totaling 26,137 patients (n = 3351 with diabetes), met study inclusion criteria. Small to moderate effect sizes were obtained for five of six domains: motor function (3 studies, n = 2374; d = -0.36), executive function (12 studies, n = 1784; d = -0.33), processing speed (16 studies, n = 3076; d = -0.33), verbal memory (15 studies, n = 4,608; d = -0.28), and visual memory (6 studies, n = 1754; d = -0.26). Effect size was smallest for attention/concentration (14 studies, n = 23,143; d = -0.19). The following tests demonstrated the most notable performance decrements in diabetes samples: Grooved Pegboard (dominant hand) (d = -0.60), Rey Auditory Verbal Learning Test (immediate) (d = -0.40), Trails B (d = -0.39), Rey-Osterreith Complex Figure (delayed) (d = -0.38), Trails A (d = -0.34), and Stroop Part I (d = -0.28). This study provides effect sizes to power future epidemiological and clinical diabetes research studies examining cognitive function and to help inform the selection of neuropsychological tests.

KW - Assessment

KW - Cardiovascular disease

KW - Central nervous system

KW - Chronic disease

KW - Endocrine

KW - Metabolic disorders

UR - http://www.scopus.com/inward/record.url?scp=84927697394&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927697394&partnerID=8YFLogxK

U2 - 10.1017/S1355617713001483

DO - 10.1017/S1355617713001483

M3 - Article

C2 - 24555960

AN - SCOPUS:84927697394

VL - 20

SP - 278

EP - 291

JO - Journal of the International Neuropsychological Society

JF - Journal of the International Neuropsychological Society

SN - 1355-6177

IS - 3

ER -